LGALS1

Across TCGA pan-cancer cohorts, LGALS1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LGALS1 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LGALS1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LGALS1 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CCRCC, LSCC, and GBM are the cancer types where LGALS1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.572	0.911	<.001	71	view →
LSCC	DFS	Median	II,III,IV	0.482	0.897	<.001	40	view →
GBM	DFS	Tertile	All	0.191	0.513	<.001	31	view →
UCEC	DFS	Tertile	III,IV	0.280	1.000	.013	20	view →
PDAC	DFS	Quartile	III,IV	0.227	0.782	.021	10	view →
LUAD	DFS	Quartile	II,III,IV	0.793	0.356	.028	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LGALS1–CCRCC (DFS)

Open the CCRCC breakdown →